The cumulative vaccination of COVID-19 vaccine in China is nearly 2.4 billion doses, and the elderly should be fully promoted.

CCTV News:China has been vaccinated with COVID-19 vaccine since December last year. Up to now, it has been vaccinated with COVID-19 vaccine for nearly 2.4 billion doses, and the vaccination rate of the whole population is in the leading position in the world. Clinical research results show that COVID-19 vaccine in China has good safety and effectiveness. Zheng Zhongwei, the head of the working group of vaccine research and development special class of the State Council Joint Prevention and Control Mechanism, recently responded to some hot issues about vaccination in an exclusive interview with CCTV reporters at the General Station.

At present, 13 COVID-19 vaccines have entered Phase III clinical trials in China, 4 COVID-19 vaccines have been approved for conditional marketing, and 3 COVID-19 vaccines have been approved for emergency use. Vaccine research and development and production have always been in the first phalanx in the world. At the same time, China regards the new crown vaccine as a global public product, and has provided more than 1.7 billion doses of COVID-19 vaccine to more than 110 countries and international organizations around the world.

COVID-19 vaccine in China has a significant effect on preventing severe illness and death.

A few days ago, the consultant of Chilean Ministry of Health published the world’s largest real-world study of COVID-19 vaccine for 10 million people in the New England Journal of Medicine. The results showed that the overall protection was 65.9% after 14 days of inoculation with the second dose of inactivated vaccine of Kexing Zhongwei, and the protection against hospitalization, severe illness and death was 87.5%, 90.3% and 86.3% respectively. According to the report of the Ministry of Health of Peru, 60,593 doctors were vaccinated with the inactivated COVID-19 vaccine of Sinopharm Group China, and the mortality rate after two doses of vaccination was reduced by 98%. The Argentine Ministry of Health issued a report that the overall death protection rate of people over 60 years old was 84% after being inoculated with two doses of China Bio-COVID-19 Inactivated Vaccine of Sinopharm Group.

Zheng Zhongwei, head of the working group of vaccine research and development special class of scientific research group of the State Council joint prevention and control mechanism:This judgment can also be made for some epidemic situations that occurred in China last year and this year. For example, Delta strain was the main virus strain that spread in China from Guangdong (May and June this year), from Guangdong, Jiangsu and Fujian to Inner Mongolia, Gansu and Qinghai. Although there were many outbreaks, the number of infected people and severe cases were completely different from those of last year’s Xinfadi in Beijing and Gaocheng in Shijiazhuang, Hebei. Therefore, the country has played a very important role in rapidly promoting mass vaccination from this year.

China has completed the preclinical study of inactivated Delta strain vaccine.

Real-world research shows that China’s vaccine has a clear effect on the infection caused by various main variants prevalent in different regions and the re-transmission after infection, and has a significant effect on preventing severe illness and death. Judging from the recent epidemic situation in China, the domestic vaccine is still effective against Delta strain. However, in order to be prepared, various vaccine research and development units have carried out a series of work for various mutant vaccines.

Make every effort to promote COVID-19 vaccine for the elderly.

At present, the vaccination rate of the whole population in China is leading in the world, but the vaccination rate of the elderly is relatively low, and the risk of COVID-19 infection among the elderly is much higher than that of the young. Therefore, at present, a key issue in promoting COVID-19 vaccination in China is to fully promote COVID-19 vaccination for the elderly, especially the very old.

Experts stressed that because the immune function of the elderly is relatively weak, the antibody level produced by people over 60 years old after vaccination is 18-mdash; The 59-year-old population is relatively low, and once infected, the proportion of severe and critical illness is higher. Therefore, it is strongly recommended that the elderly not only receive two doses of vaccine as soon as possible, but also strengthen immunization six months after completing the two doses of vaccination, in order to obtain better protection effect.

Inoculation with booster needle can enhance the prevention and control ability of mutant

At present, many countries have carried out the work of strengthening immunization, and China has also specially organized experts to demonstrate the strategy of strengthening immunization of vaccines in COVID-19. Studies have shown that after the third dose of inactivated vaccine is used to strengthen immunity, not only the antibody level is greatly improved, but also the ability to prevent and control various mutant strains is stronger.

Zheng Zhongwei, head of the working group of vaccine research and development special class of scientific research group of the State Council joint prevention and control mechanism:Strengthening (immunization) with the same technical route is relatively safer. After vaccination with different technical routes, the antibody level will be more improved, and some abnormal reactions and adverse reactions of the vaccinators may be higher, but this adverse reaction can be tolerated by the vaccinators.

China will launch different technical routes to strengthen immune combination.

The research shows that the same technical route and different technical routes can greatly improve the antibody level, and the safety is also clearly guaranteed. Zheng Zhongwei said that the next step will be to combine the results of clinical research, organize expert argumentation, and launch the optimal combination of enhanced immunization based on the principle of safety and effectiveness.